NCT00568139进行中(未招募)不适用
Evaluierung Von Nebenwirkungen Einer Therapie Mit Mitotane Beim Nebennierenkarzinom- Evaluation of Side Effects of Mitotane in Adrenocortical Carcinoma
University of Wuerzburg2 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2008年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 400
- 试验地点
- 2
- 主要终点
- Documentation of adverse effects
研究概览
简要总结
Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adrenocortical carcinoma
- •Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)
排除标准
- 未提供
结局指标
主要结局
Documentation of adverse effects
时间窗: from starting mitotane until discontinuation of mitotane (since this is very variable from patient to patient no specific number of days or weeks can be entered (standard therapy would be about 2 years) or start of additional other medical therapies
Adverse effects will be documented using the NCI CTC AE v5.5
次要结局
未报告次要终点
研究者
Martin Fassnacht
Head of Endocrinology
University of Wuerzburg
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical CarcinomaAdrenocortical CarcinomaNCT05839886Shanghai Jiao Tong University School of Medicine50
招募中
4 期
Mitotane Therapeutic Drug Monitoring Study: Assessing Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and AdultsAdrenocortical cancerCancer - Other cancer typesACTRN12613000058774Calvary Mater Newcastle60
Unknown
3 期
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)Adrenocortical CarcinomaNCT00777244University of Turin, Italy200
已完成
3 期
Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInomaAdrenocortical CarcinomaNCT03723941Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia40
已完成
1 期
A Safety and Feasibility Study of Mitotane in Prostate CancerProstate CancerNCT02057237University Health Network, Toronto1
